Corient Private Wealth
GTBP icon

Corient Private Wealth’s GT Biopharma GTBP Stock Holding History

Corient Private Wealth’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.79K Buy
+20,000
New +$8.11K ﹤0.01% 3036

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Corient Private Wealth's GTBP Position: Q2 2026 in Review

Corient Private Wealth opened a new position in GT Biopharma (GTBP) in Q2 2026: 20,000 shares worth $9.79K. The stake represents ﹤0.01% of the portfolio and ranks #3036 among its holdings.

59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Corient Private Wealth held 20,000 shares of GT Biopharma worth $9.79K as of Q2 2026.
  • GT Biopharma was a new Corient Private Wealth position in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #3036 holding.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.